甲状腺髓样癌：所综述的第三常见的甲状腺癌。
Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.
作者信息
Stamatakos Michael, Paraskeva Panoraia, Stefanaki Charikleia, Katsaronis Paraskevas, Lazaris Andreas, Safioleas Konstantinos, Kontzoglou Konstantinos
机构信息
Fourth Department of Surgery, School of Medicine, Athens University, Attikon Hospital, Athens, Greece.
出版信息
Oncol Lett. 2011 Jan;2(1):49-53. doi: 10.3892/ol.2010.223. Epub 2010 Nov 23.
Abstract
Medullary thyroid cancer is a type of thyroid cancer of neuroendocrine origin. It occurs in hereditary and sporadic forms, and its aggressive behavior is associated with the clinical presentation and type of RET mutation. Total thyroidectomy remains the ideal choice of treatment. Early diagnosis and treatment are the fundamental for a 100% cure rate. In this study, we present our experience of 3 cases, along with a complete review of the literature derived from a Pubmed Database search.
摘要
髓样甲状腺癌是一种神经内分泌起源的甲状腺癌。它以遗传性和散发性形式出现，其侵袭性行为与RET突变的临床表现和类型相关。全甲状腺切除术仍然是理想的治疗选择。早期诊断和治疗是实现100%治愈率的根本。在本研究中，我们介绍了3例病例的经验，并对通过PubMed数据库检索获得的文献进行了全面综述。
相似文献
1
Medullary thyroid carcinoma: The third most common thyroid cancer reviewed.甲状腺髓样癌：所综述的第三常见的甲状腺癌。
Oncol Lett. 2011 Jan;2(1):49-53. doi: 10.3892/ol.2010.223. Epub 2010 Nov 23.
2
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.遗传性和散发性甲状腺髓样癌的基因诊断的临床实用性。
Ann Endocrinol (Paris). 2019 Jun;80(3):187-190. doi: 10.1016/j.ando.2019.04.014. Epub 2019 Apr 11.
3
Surgical approach to the management of medullary thyroid cancer: when is lymph node dissection needed?甲状腺髓样癌的外科治疗策略：何时需要进行淋巴结清扫术？
Oncology. 2013;84(6):350-5. doi: 10.1159/000351148. Epub 2013 May 14.
4
New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.87岁伴有高危RET原癌基因密码子620突变的家族性甲状腺髓样癌新病例报告
J Laryngol Otol. 2009 Jul;123(7):796-800. doi: 10.1017/S0022215108003472. Epub 2008 Sep 4.
5
RET proto oncogene mutation detection and medullary thyroid carcinoma prevention.RET原癌基因突变检测与甲状腺髓样癌预防
Asian Pac J Cancer Prev. 2015;16(6):2107-17. doi: 10.7314/apjcp.2015.16.6.2107.
6
Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age.小儿髓样甲状腺癌的外科治疗
Curr Pediatr Rev. 2016;12(4):280-285. doi: 10.2174/1573396313666161111120936.
7
Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.RET 原癌基因突变的多样性及其在甲状腺髓样癌中的致癌机制。
Crit Rev Clin Lab Sci. 2016 Aug;53(4):217-27. doi: 10.3109/10408363.2015.1129529. Epub 2016 Jan 27.
8
Late-onset medullary carcinoma of the thyroid: need for genetic testing and prophylactic thyroidectomy in adult family members.甲状腺髓样癌的迟发性发病：成年家庭成员进行基因检测和预防性甲状腺切除术的必要性。
Laryngoscope. 2006 Sep;116(9):1704-7. doi: 10.1097/01.mlg.0000233509.83679.ee.
9
Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.降钙素和 CEA 双阴性甲状腺髓样癌 1 例报告及文献复习
BMC Endocr Disord. 2019 Oct 16;19(1):103. doi: 10.1186/s12902-019-0435-7.
10
Medullary thyroid carcinoma--update and present management controversies.甲状腺髓样癌——最新进展及当前治疗争议
Ann R Coll Surg Engl. 2006 Sep;88(5):433-8. doi: 10.1308/003588406X117043.
引用本文的文献
1
The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs.甲状腺癌治疗中靶向治疗的革命：当前及未来有前景的抗癌药物
Int J Mol Sci. 2025 Apr 12;26(8):3663. doi: 10.3390/ijms26083663.
2
The Efficacy and Safety of Anlotinib in the Treatment of Thyroid Cancer: A Systematic Review.安罗替尼治疗甲状腺癌的疗效与安全性：一项系统评价
J Clin Med. 2025 Jan 8;14(2):338. doi: 10.3390/jcm14020338.
3
A novel role for nonactin: interfering with G-quadruplex in RET-driven medullary thyroid cancer.诺阿卡菌素的新作用：干扰RET驱动的甲状腺髓样癌中的G-四链体。
BMC Cancer. 2024 Dec 23;24(1):1569. doi: 10.1186/s12885-024-13345-9.
4
Limited Thyroidectomy Achieves Equivalent Survival to Total Thyroidectomy for Early Localized Medullary Thyroid Cancer.对于早期局限性甲状腺髓样癌，甲状腺次全切除术与甲状腺全切除术的生存率相当。
Cancers (Basel). 2024 Dec 4;16(23):4062. doi: 10.3390/cancers16234062.
5
Non-secretory medullary thyroid carcinoma with laryngotracheal invasion: a case report and review of the literature.伴喉气管侵犯的非分泌型甲状腺髓样癌：一例报告并文献复习
AME Case Rep. 2024 Aug 2;8:87. doi: 10.21037/acr-24-45. eCollection 2024.
6
LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.LINC00887 通过与 FOXQ1 结合作为增强子 RNA 促进甲状腺髓样癌的进展。
Curr Cancer Drug Targets. 2024;24(5):519-533. doi: 10.2174/0115680096258716231026063704.
7
The Evolving Treatment Landscape of Medullary Thyroid Cancer.甲状腺髓样癌的治疗进展。
Curr Treat Options Oncol. 2023 Dec;24(12):1815-1832. doi: 10.1007/s11864-023-01145-5. Epub 2023 Nov 18.
8
Development of the First F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety.通过螯合部分的取代开发首个具有高靶点亲和力和肿瘤蓄积性的基于F标记放射性杂交体的小分子胃泌素衍生物。
Pharmaceutics. 2023 Mar 3;15(3):826. doi: 10.3390/pharmaceutics15030826.
9
Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.将一个硅氟烷基团引入DOTA-PP-F11N的D-谷氨酸链中可产生基于放射性杂交的CCK-2R靶向化合物，其体内药代动力学得到改善。
Pharmaceuticals (Basel). 2022 Nov 25;15(12):1467. doi: 10.3390/ph15121467.
10
Synchronous Hürthle cell and medullary thyroid carcinomas.同步 Hurthle 细胞和髓样甲状腺癌。
BMJ Case Rep. 2022 May 31;15(5):e248879. doi: 10.1136/bcr-2022-248879.
本文引用的文献
1
Sonography and fine-needle aspiration biopsy in the diagnosis of benign versus malignant nodules in patients with autoimmune thyroiditis.超声检查及细针穿刺活检在自身免疫性甲状腺炎患者良性与恶性结节诊断中的应用
J Clin Ultrasound. 2009 Nov-Dec;37(9):487-92. doi: 10.1002/jcu.20633.
2
Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.高钙血症并非甲状腺髓样癌的特征性表现。
Clinics (Sao Paulo). 2009;64(7):699-706. doi: 10.1590/S1807-59322009000700015.
3
Surgical approaches in thyroid cancer and lymph-node metastases.甲状腺癌及淋巴结转移的手术治疗方法
Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):971-87. doi: 10.1016/j.beem.2008.09.018.
4
Current management of medullary thyroid cancer.甲状腺髓样癌的当前管理
Oncologist. 2008 May;13(5):539-47. doi: 10.1634/theoncologist.2007-0239.
5
New therapeutic approaches to treat medullary thyroid carcinoma.治疗甲状腺髓样癌的新治疗方法。
Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):22-32. doi: 10.1038/ncpendmet0717.
6
Molecular mechanisms of medullary thyroid carcinoma: current approaches in diagnosis and treatment.甲状腺髓样癌的分子机制：当前的诊断和治疗方法
Histol Histopathol. 2008 Jan;23(1):109-16. doi: 10.14670/HH-23.109.
7
Cell lineage-specific interactions between Men1 and Rb in neuroendocrine neoplasia.神经内分泌肿瘤中Men1与Rb之间的细胞谱系特异性相互作用。
Carcinogenesis. 2008 Mar;29(3):620-8. doi: 10.1093/carcin/bgm207. Epub 2007 Sep 24.
8
Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma.核医学程序在甲状腺髓样癌诊断与治疗中的应用
Biomed Pharmacother. 2008 Mar;62(3):139-46. doi: 10.1016/j.biopha.2007.07.011. Epub 2007 Aug 20.
9
Surgical approach to medullary thyroid cancer.
Arq Bras Endocrinol Metabol. 2007 Jul;51(5):818-24. doi: 10.1590/s0004-27302007000500020.
10
Neck management in medullary thyroid carcinoma.甲状腺髓样癌的颈部处理
Eur J Surg Oncol. 2008 Jan;34(1):71-6. doi: 10.1016/j.ejso.2007.03.020. Epub 2007 Jun 6.
Zotero 插件